These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Ziemer CM; Miedema J; Smith CJ; Liu Z; Thomas NE; Googe PB Am J Dermatopathol; 2021 Apr; 43(4):318-320. PubMed ID: 33055536 [No Abstract] [Full Text] [Related]
9. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome]. Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090 [No Abstract] [Full Text] [Related]
10. Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma. Gallo Marin B; Oliva R; Kahn B; Borgovan T; Brooks BE; Massoud CM R I Med J (2013); 2022 Apr; 105(3):34-36. PubMed ID: 35349618 [TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-Associated Stevens-Johnson Syndrome in a Patient With Metastatic Non-small Cell Lung Cancer: A Case Report. Sandhu M; Kc B; Bhandari J; Gambhir HS; Farah R Cureus; 2023 Jul; 15(7):e41439. PubMed ID: 37546048 [TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer. Riano I; Cristancho C; Treadwell T J Investig Med High Impact Case Rep; 2020; 8():2324709620914796. PubMed ID: 32207346 [TBL] [Abstract][Full Text] [Related]
13. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment. Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201 [TBL] [Abstract][Full Text] [Related]
14. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma. Boruah PK; Bolesta S; Shetty SM Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596 [TBL] [Abstract][Full Text] [Related]
15. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164 [TBL] [Abstract][Full Text] [Related]
16. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941 [TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction. Neema S; Sathu S; Vasudevan B; Shreshta S; Bhatt S; K L Indian J Dermatol Venereol Leprol; 2023; 89(4):589-591. PubMed ID: 37067146 [No Abstract] [Full Text] [Related]
18. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Power WJ; Ghoraishi M; Merayo-Lloves J; Neves RA; Foster CS Ophthalmology; 1995 Nov; 102(11):1669-76. PubMed ID: 9098260 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936 [TBL] [Abstract][Full Text] [Related]
20. Polymyalgia rheumatica due to pembrolizumab therapy. Iskandar A; Hwang A; Dasanu CA J Oncol Pharm Pract; 2019 Jul; 25(5):1282-1284. PubMed ID: 30249155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]